.
pubblicato il 3 dicembre....:
Minimal
evidence for cardiotoxicity in anthracycline-pretreated patients with refractory-relapsed non
Hodgkin’s lymphoma was observed with the novel anthracenedione, pixantrone.
ecco Aragingo le riviste scientifiche, che dici sarà la volta buona?
Redox inactivity in the face of high cardiac uptake
suggests that pixantrone might be safe also in doxorubicin-naïve patients.
......Lack of intramyocardial toxic bioactivation suggests that PIX could be of value also as firstline agent........
....In conclusion, PIX differs from both DOX and MITOX in a translational model of human
myocardium. This information endorses development of PIX as a new agent for active and safe
therapy for NHL.